British Virgin Islands vs India: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
British Virgin Islands
0.2%
in 2024
India
0.2%
in 2024
British Virgin Islands rank
78th
India rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- British Virgin Islands
- India
How they compare
British Virgin Islands currently reports 0.2% against 0.2% in India, a difference of 0.0%.
Across all 10 years both countries report, India has been ahead every year.
British Virgin Islands ranks 78th and India ranks 78th of 215 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | British Virgin Islands | India | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.4% | 0.1% | India |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, British Virgin Islands or India?
- British Virgin Islands, at 0.2% against 0.2% in India as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between British Virgin Islands and India?
- 0.0%, with British Virgin Islands ahead.
- How many years of comparable data are there for British Virgin Islands and India?
- 10 years are reported by both, from 2015 to 2024.
- How do British Virgin Islands and India rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- British Virgin Islands ranks 78th and India ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.